Skip to content
⌘KStart free
AI InfrastructureDefenseQuantumAll studies →

Signatera-Guided De-escalation of Adjuvant Therapy in Resectable Stage II-IVa Gastric/Gastric-Esophageal Cancer

← catalyst calendar

NCT07565857 · readout ≤ 772 d

Sponsored by Natera, Inc. (industry) · NTRA — their whole pipeline →.

Phase
Not applicable
Status
Not yet recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
1,000estimated

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
StartSep 2026estimatedWhen the study began enrolling
Primary completionSep 2028estimatedThe date the last participant is measured for the primary outcome — the readout window
Study completionSep 2034estimatedThe whole study's end, after follow-up
First posted2026-05-04actualWhen this record first appeared on the registry
Results posted—When the sponsor posted results to the registry
Record updated2026-05-04actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Gastric-Esophageal Cancer

Intervention

  • Device: Signatera Genome ultra-sensitive ctDNA blood test

Primary outcome

what the primary-completion date above is the date OF
Disease Free Survival (DFS)
measured 2 years from randomization to the first occurrence of disease recurrence or death from any cause, whichever occurs first

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · NTRA's whole pipeline · Catalyst calendar · Every registered study · What changed

Related →Calendar (CAL)Screener (SCR)Watchlist (WL)